Using their cutting-edge drug design technologies, Prazer Therapeutics pioneers the creation of novel drugs to help patients with intractable diseases. Their SPiDEM platform, based on rational drug design and targeted protein degradation, has shown superior efficacy and reduced drug resistance compared to existing technologies. Prazer's pipeline includes potential treatments for neurodegenerative diseases, cancers, inflammatory diseases, chronic hepatitis B, and acute lung inflammation caused by coronaviruses, influenza viruses, and RSV.